Loading...
XSHE
000952
Market cap335mUSD
Oct 09, Last price  
6.69CNY
1D
2.45%
1Q
18.62%
Jan 2017
-58.00%
Name

Hubei Guangji Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:000952 chart
P/E
—
P/S
3.69
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.50%
Rev. gr., 5y
-4.50%
Revenues
624m
-2.32%
571,782,750448,197,426483,316,187453,316,737394,156,326487,080,365485,858,037560,355,471714,723,952801,556,324843,830,941731,340,516688,169,322837,106,649785,573,170797,642,746797,642,745737,819,478638,801,582623,974,702
Net income
-404m
L+36.98%
89,097,44543,003,75313,979,6024,845,510-95,564,0732,421,982-218,730,74120,921,473141,839,237105,211,601171,728,91786,943,19574,647,107110,107,173110,107,17650,333,65450,333,658-140,248,067-295,291,149-404,494,390
CFO
60m
+9,120.62%
125,954,626331,975,678220,700,152077,177,84081,878,424108,020,36495,158,31400167,074,831178,828,210231,438,796144,200,478119,381,52575,907,30345,079,614-148,963,590655,35760,427,978
Dividend
May 27, 20220.06 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hubei Guangji Pharmaceutical Co., Ltd. engages in the production and operation of pharmaceutical raw materials, pharmaceutical preparations, and feed additives. It specializes in production of vitamin B2, B6 and pharmaceutical products. Vitamin B2, is also known as riboflavin. it is used in medicine APIs (Active Pharmaceutical Ingredient), feed additives, and food additives. Its products are divided into raw material series products and preparation series products. The series of raw materials are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade nuclear yellow and riboflavin sodium phosphate. The preparation series products are oral solid preparations and large infusions. The company was founded on May 28, 1993 and is headquartered in Wuxue, China.

Key people

Ligang Hu
Chairman of the Board · since 2024
Yi Xiong
Chief Financial Officer · since 2024
Cheng Gong
General Manager, Director · since 2024
Lin Yang
General Manager · since 2024
Zhanghua Cheng
Deputy General Manager · since 2011
Zhi Fang
Deputy General Manager, Director, Chief Engineer · since 2024
Mingfeng Hu
Deputy General Manager · since 2024
Zhengdong Lu
Deputy General Manager · since 2018
Zhongyi Ruan
Deputy General Manager · since 2018
Xin Wang
Deputy General Manager · since 2011
Yanhua Zhao
Deputy General Manager · since 2024
Xinghu Yang
Secretary of the Board · since 2025
Bin Zheng
Secretary of the Board · since 2021
Shaozhi Guo
Deputy General Manager, Director · since 2018
Bo Liu
Director · since 2024
Shoudong Shi
Director · since 2024
Wei Guo
Independent Director · since 2024
Kui Hong
Independent Director · since 2024
Jianming Mei
Independent Director · since 2024
IPO date
Nov 12, 1999
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
湖北武穴市江堤路1号
黄冈市, HB 430000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT